North America (NAFTA) Generics Market Summary, Competitive Analysis and Forecast to 2027
North America (NAFTA) Generics Market Summary, Competitive Analysis and Forecast to 2027
Summary
The NAFTA Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2018-22, and forecast to 2027). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
Summary
The NAFTA Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2018-22, and forecast to 2027). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
- The North American Free Trade Agreement (NAFTA) is a trade agreement between the countries in North America: the US, Canada and Mexico. The generics industry within the NAFTA countries had a total market value of $82,183.1 million in 2022.The Canada was the fastest growing country, with a CAGR of 4.7% over the 2018-22 period.
- Within the generics industry, the US is the leading country among the NAFTA bloc, with market revenues of $69,916.7 million in 2022. This was followed by Canada and Mexico, with a value of $6,229.7 and $6,036.8 million, respectively.
- The US is expected to lead the generics industry in the NAFTA bloc, with a value of $82,184.5 million in 2027, followed by Canada and Mexico with expected values of $8,709.6 and $7,402.3 million, respectively.
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the NAFTA generics market
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the NAFTA generics market
- Leading company profiles reveal details of key generics market players’ NAFTA operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the NAFTA generics market with five year forecasts by both value and volume
- Compares data from the US, Canada and Mexico, alongside individual chapters on each country
- What was the size of the NAFTA generics market by value in 2022?
- What will be the size of the NAFTA generics market in 2027?
- What factors are affecting the strength of competition in the NAFTA generics market?
- How has the market performed over the last five years?
- How large is the NAFTA generics market in relation to its regional counterparts?
1 INTRODUCTION
1.1. What is this report about?
1.2. Who is the target reader?
1.3. How to use this report
1.4. Definitions
2 NAFTA GENERICS
2.1. Industry Outlook
3 GENERICS IN CANADA
3.1. Market Overview
3.2. Market Data
3.3. Market Segmentation
3.4. Market outlook
3.5. Five forces analysis
4 MACROECONOMIC INDICATORS
4.1. Country data
5 GENERICS IN MEXICO
5.1. Market Overview
5.2. Market Data
5.3. Market Segmentation
5.4. Market outlook
5.5. Five forces analysis
6 MACROECONOMIC INDICATORS
6.1. Country data
7 GENERICS IN THE UNITED STATES
7.1. Market Overview
7.2. Market Data
7.3. Market Segmentation
7.4. Market outlook
7.5. Five forces analysis
8 MACROECONOMIC INDICATORS
8.1. Country data
9 COMPANY PROFILES
9.1. Novartis AG
9.2. Teva Pharmaceutical Industries Limited
9.3. Viatris Inc.
9.4. Apotex, Inc.
9.5. Sun Pharmaceutical Industries Ltd
9.6. Aurobindo Pharma Ltd
9.7. Pfizer Inc.
10 APPENDIX
10.1. Methodology
10.2. About MarketLine
1.1. What is this report about?
1.2. Who is the target reader?
1.3. How to use this report
1.4. Definitions
2 NAFTA GENERICS
2.1. Industry Outlook
3 GENERICS IN CANADA
3.1. Market Overview
3.2. Market Data
3.3. Market Segmentation
3.4. Market outlook
3.5. Five forces analysis
4 MACROECONOMIC INDICATORS
4.1. Country data
5 GENERICS IN MEXICO
5.1. Market Overview
5.2. Market Data
5.3. Market Segmentation
5.4. Market outlook
5.5. Five forces analysis
6 MACROECONOMIC INDICATORS
6.1. Country data
7 GENERICS IN THE UNITED STATES
7.1. Market Overview
7.2. Market Data
7.3. Market Segmentation
7.4. Market outlook
7.5. Five forces analysis
8 MACROECONOMIC INDICATORS
8.1. Country data
9 COMPANY PROFILES
9.1. Novartis AG
9.2. Teva Pharmaceutical Industries Limited
9.3. Viatris Inc.
9.4. Apotex, Inc.
9.5. Sun Pharmaceutical Industries Ltd
9.6. Aurobindo Pharma Ltd
9.7. Pfizer Inc.
10 APPENDIX
10.1. Methodology
10.2. About MarketLine
LIST OF TABLES
Table 1: NAFTA countries generics industry, revenue ($m), 2018-27
Table 2: NAFTA countries generics industry, revenue ($m), 2018-22
Table 3: NAFTA countries generics industry forecast, revenue ($m), 2022-27
Table 4: Canada generics market value: $ million, 2017-22
Table 5: Canada generics market volume: %, 2017-22
Table 6: Canada generics market geography segmentation: $ million, 2022
Table 7: Canada generics market value forecast: $ million, 2022-27
Table 8: Canada generics market volume forecast: %, 2022-27
Table 9: Canada size of population (million), 2018-22
Table 10: Canada gdp (constant 2005 prices, $ billion), 2018-22
Table 11: Canada gdp (current prices, $ billion), 2018-22
Table 12: Canada inflation, 2018-22
Table 13: Canada consumer price index (absolute), 2018-22
Table 14: Canada exchange rate, 2018-22
Table 15: Mexico generics market value: $ million, 2017-22
Table 16: Mexico generics market volume: %, 2017-22
Table 17: Mexico generics market geography segmentation: $ million, 2022
Table 18: Mexico generics market value forecast: $ million, 2022-27
Table 19: Mexico generics market volume forecast: %, 2022-27
Table 20: Mexico size of population (million), 2018-22
Table 21: Mexico gdp (constant 2005 prices, $ billion), 2018-22
Table 22: Mexico gdp (current prices, $ billion), 2018-22
Table 23: Mexico inflation, 2018-22
Table 24: Mexico consumer price index (absolute), 2018-22
Table 25: Mexico exchange rate, 2018-22
Table 26: United States generics market value: $ million, 2017-22
Table 27: United States generics market volume: %, 2017-22
Table 28: United States generics market geography segmentation: $ million, 2022
Table 29: United States generics market value forecast: $ million, 2022-27
Table 30: United States generics market volume forecast: %, 2022-27
Table 31: United States size of population (million), 2018-22
Table 32: United States gdp (constant 2005 prices, $ billion), 2018-22
Table 33: United States gdp (current prices, $ billion), 2018-22
Table 34: United States inflation, 2018-22
Table 35: United States consumer price index (absolute), 2018-22
Table 36: United States exchange rate, 2018-22
Table 37: Novartis AG: key facts
Table 38: Novartis AG: Annual Financial Ratios
Table 39: Novartis AG: Key Employees
Table 40: Novartis AG: Key Employees Continued
Table 41: Teva Pharmaceutical Industries Limited: key facts
Table 42: Teva Pharmaceutical Industries Limited: Annual Financial Ratios
Table 43: Teva Pharmaceutical Industries Limited: Key Employees
Table 44: Viatris Inc.: key facts
Table 45: Viatris Inc.: Annual Financial Ratios
Table 46: Viatris Inc.: Key Employees
Table 47: Viatris Inc.: Key Employees Continued
Table 48: Apotex, Inc.: key facts
Table 49: Apotex, Inc.: Key Employees
Table 50: Sun Pharmaceutical Industries Ltd: key facts
Table 51: Sun Pharmaceutical Industries Ltd: Annual Financial Ratios
Table 52: Sun Pharmaceutical Industries Ltd: Key Employees
Table 53: Aurobindo Pharma Ltd: key facts
Table 54: Aurobindo Pharma Ltd: Annual Financial Ratios
Table 55: Aurobindo Pharma Ltd: Key Employees
Table 56: Pfizer Inc.: key facts
Table 57: Pfizer Inc.: Annual Financial Ratios
Table 58: Pfizer Inc.: Key Employees
Table 59: Pfizer Inc.: Key Employees Continued
Table 1: NAFTA countries generics industry, revenue ($m), 2018-27
Table 2: NAFTA countries generics industry, revenue ($m), 2018-22
Table 3: NAFTA countries generics industry forecast, revenue ($m), 2022-27
Table 4: Canada generics market value: $ million, 2017-22
Table 5: Canada generics market volume: %, 2017-22
Table 6: Canada generics market geography segmentation: $ million, 2022
Table 7: Canada generics market value forecast: $ million, 2022-27
Table 8: Canada generics market volume forecast: %, 2022-27
Table 9: Canada size of population (million), 2018-22
Table 10: Canada gdp (constant 2005 prices, $ billion), 2018-22
Table 11: Canada gdp (current prices, $ billion), 2018-22
Table 12: Canada inflation, 2018-22
Table 13: Canada consumer price index (absolute), 2018-22
Table 14: Canada exchange rate, 2018-22
Table 15: Mexico generics market value: $ million, 2017-22
Table 16: Mexico generics market volume: %, 2017-22
Table 17: Mexico generics market geography segmentation: $ million, 2022
Table 18: Mexico generics market value forecast: $ million, 2022-27
Table 19: Mexico generics market volume forecast: %, 2022-27
Table 20: Mexico size of population (million), 2018-22
Table 21: Mexico gdp (constant 2005 prices, $ billion), 2018-22
Table 22: Mexico gdp (current prices, $ billion), 2018-22
Table 23: Mexico inflation, 2018-22
Table 24: Mexico consumer price index (absolute), 2018-22
Table 25: Mexico exchange rate, 2018-22
Table 26: United States generics market value: $ million, 2017-22
Table 27: United States generics market volume: %, 2017-22
Table 28: United States generics market geography segmentation: $ million, 2022
Table 29: United States generics market value forecast: $ million, 2022-27
Table 30: United States generics market volume forecast: %, 2022-27
Table 31: United States size of population (million), 2018-22
Table 32: United States gdp (constant 2005 prices, $ billion), 2018-22
Table 33: United States gdp (current prices, $ billion), 2018-22
Table 34: United States inflation, 2018-22
Table 35: United States consumer price index (absolute), 2018-22
Table 36: United States exchange rate, 2018-22
Table 37: Novartis AG: key facts
Table 38: Novartis AG: Annual Financial Ratios
Table 39: Novartis AG: Key Employees
Table 40: Novartis AG: Key Employees Continued
Table 41: Teva Pharmaceutical Industries Limited: key facts
Table 42: Teva Pharmaceutical Industries Limited: Annual Financial Ratios
Table 43: Teva Pharmaceutical Industries Limited: Key Employees
Table 44: Viatris Inc.: key facts
Table 45: Viatris Inc.: Annual Financial Ratios
Table 46: Viatris Inc.: Key Employees
Table 47: Viatris Inc.: Key Employees Continued
Table 48: Apotex, Inc.: key facts
Table 49: Apotex, Inc.: Key Employees
Table 50: Sun Pharmaceutical Industries Ltd: key facts
Table 51: Sun Pharmaceutical Industries Ltd: Annual Financial Ratios
Table 52: Sun Pharmaceutical Industries Ltd: Key Employees
Table 53: Aurobindo Pharma Ltd: key facts
Table 54: Aurobindo Pharma Ltd: Annual Financial Ratios
Table 55: Aurobindo Pharma Ltd: Key Employees
Table 56: Pfizer Inc.: key facts
Table 57: Pfizer Inc.: Annual Financial Ratios
Table 58: Pfizer Inc.: Key Employees
Table 59: Pfizer Inc.: Key Employees Continued
